The next decade of SET:from an oncoprotein to beyond  

作　　者：Han Yao Meng Zhang Donglai Wang 

机构地区：[1]State Key Laboratory of Common Mechanism Research for Major Diseases&Department of Medical Genetics,Institute of Basic Medical Sciences&School of Basic Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100005,China

出　　处：《Journal of Molecular Cell Biology》2024年第1期1-14,共14页分子细胞生物学报（英文版）

基　　金：supported by the National Natural ScienceFoundation of China(82073132,82122054,81872311,and82203340);the Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences(2021-I2M-1-016 and2022-I2M-JB-003);the Fundamental Research Funds for theCentral Universities(3332023147);the Overseas ExpertiseIntroduction Center for Discipline Innovation(‘111 Center’;BP0820029);the State Key Laboratory Special Fund(2060204).

摘　　要：This year marks the fourth decade of research into the protein SET,which was discovered in 1992.SET was initially identified as an oncoprotein but later shown to be a multifaceted protein involved in regulating numerous biological processes under both physiological and pathophysiological conditions.SET dysfunction is closely associated with diseases,such as cancer and Alzheimer's disease.With the increasing understanding of how SET works and how it is regulated in cells,targeting aberrant SET has emerged as a potential strategy for disease intervention.In this review,we present a comprehensive overview of the advancements in SET studies,encompassing its biological functions,regulatory networks,clinical implications,and pharmacological inhibitors.Furthermore,we provide insights into the future prospects of SET research,with a particular emphasis on its promising potential in the realm of immune modulation.

关 键 词：SET biological process regulatory mechanism DISEASE THERAPY 

分 类 号：Q51[生物学—生物化学]